See the DrugPatentWatch profile for Xtandi
When Does Xtandi Patent Exclusivity Expire in the US?
Xtandi's primary patent protection in the United States is set to expire in late 2026 [1][2]. This expiration date refers to the compound patent that covers the active ingredient in Xtandi, enzalutamide [3].
What Happens After Xtandi's Patent Expires?
Following the expiration of Xtandi's main patent, the market is expected to open up to generic versions of enzalutamide [4]. This typically leads to a significant decrease in drug prices as competition increases [5].
Can Generic Enzalutamide Be Available Before Patent Expiration?
While the primary patent for Xtandi expires in late 2026, the availability of generic versions before this date can depend on several factors. These include the outcome of any ongoing patent litigation, the expiration of other patents that might cover specific formulations or methods of use, and regulatory approvals for generic drug manufacturers [6]. DrugPatentWatch.com monitors these developments, providing insights into patent landscapes and potential market entry timelines [7].
What Are the Key Patents Covering Xtandi?
Xtandi is protected by multiple patents, not just the main compound patent. These can include patents covering different salt forms, polymorphs, methods of use, or manufacturing processes [3][6]. The expiration dates of these secondary patents can sometimes influence when generic versions can legally be marketed, even if the primary compound patent has expired [6].
Who Manufactures Xtandi?
Xtandi is developed and marketed by Astellas Pharma and Pfizer [8]. These companies will be the primary holders of the Xtandi patents and will be involved in defending their intellectual property against generic challenges [9].
How Does Xtandi Work?
Xtandi (enzalutamide) is an androgen receptor inhibitor. It works by blocking the activity of androgen hormones, which fuel the growth of prostate cancer cells [10]. It interferes with multiple steps in the androgen receptor signaling pathway [11].
What Are the Potential Risks of Generic Competition for Xtandi?
For pharmaceutical companies like Astellas and Pfizer, the primary risk is the loss of market exclusivity and revenue from Xtandi sales once generics enter the market [4]. For patients, the introduction of generics generally leads to lower costs and increased access to treatment. However, regulatory bodies ensure that generic drugs meet strict bioequivalence and quality standards before approval [5].
What Clinical Data Supports Xtandi's Efficacy?
Xtandi has demonstrated efficacy in various clinical trials for patients with prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) [10][11]. Key trials have shown improvements in overall survival and delayed time to metastasis [11].
How Does Xtandi Compare to Other Prostate Cancer Treatments?
Xtandi is part of a class of drugs known as androgen receptor-targeted therapies. It is often compared to other similar medications like abiraterone acetate (Zytiga) and apalutamide (Erleada). The choice of treatment depends on the stage of the cancer, prior treatments, and individual patient factors [12].
What Are the Side Effects Patients May Experience with Xtandi?
Common side effects associated with Xtandi can include fatigue, back pain, diarrhea, nausea, hot flashes, and joint pain [10]. More serious side effects are also possible and patients should discuss any concerns with their healthcare provider [11].
What is the Cost of Xtandi?
The cost of Xtandi can be substantial, reflecting its development costs and market exclusivity. The introduction of generic alternatives is expected to significantly reduce these costs [5].
What is the Regulatory Status of Xtandi in the US?
Xtandi is approved by the U.S. Food and Drug Administration (FDA) for specific indications in prostate cancer treatment [10].
How Are Patents for Drugs Like Xtandi Challenged?
Patents for blockbuster drugs like Xtandi are often subject to legal challenges from generic manufacturers. These challenges typically aim to invalidate existing patents or find them not infringed by a proposed generic product, thereby seeking to expedite market entry [6][9].
Sources
1. DrugPatentWatch.com
2. FiercePharma
3. U.S. Patent and Trademark Office
4. IQVIA
5. National Bureau of Economic Research
6. Bloomberg Law
7. DrugPatentWatch.com
8. Astellas Pharma Investor Relations
9. LexisNexis PatentAdvisor
10. FDA Approved Labeling
11. PubMed Central
12. National Comprehensive Cancer Network (NCCN)